Searches , social queries for NOREPINEPHRINE RELEASING-AGENT
Search references for NOREPINEPHRINE RELEASING-AGENT. Phrases containing NOREPINEPHRINE RELEASING-AGENT
See searches and references containing NOREPINEPHRINE RELEASING-AGENT!
Search references for NOREPINEPHRINE RELEASING-AGENT. Phrases containing NOREPINEPHRINE RELEASING-AGENT
See searches and references containing NOREPINEPHRINE RELEASING-AGENT!NOREPINEPHRINE RELEASING-AGENT
Catecholaminergic type of drug
A norepinephrine releasing agent (NRA), also known as an adrenergic releasing agent, is a catecholaminergic type of drug that induces the release of norepinephrine
Norepinephrine releasing agent
Norepinephrine_releasing_agent
Type of drug
serotonin–norepinephrine–dopamine releasing agent (SNDRA), also known as a triple releasing agent (TRA), is a type of drug which induces the release of serotonin
Serotonin–norepinephrine–dopamine releasing agent
Serotonin–norepinephrine–dopamine_releasing_agent
Drug class
A norepinephrine–dopamine releasing agent (NDRA) is a type of drug which induces the release of norepinephrine (and epinephrine) and dopamine in the body
Norepinephrine–dopamine releasing agent
Norepinephrine–dopamine_releasing_agent
Drug class
A serotonin–norepinephrine releasing agent (SNRA) is a type of drug which induces the release of serotonin and norepinephrine (and epinephrine) in the
Serotonin–norepinephrine releasing agent
Serotonin–norepinephrine_releasing_agent
Type of drug
including norepinephrine–dopamine releasing agents (NDRAs) like amphetamine and methamphetamine, serotonin–norepinephrine–dopamine releasing agents (SNDRAs)
Dopamine_releasing_agent
Drug that inhibits the reuptake of norepinephrine and dopamine
monoamine releasing agents. Norepinephrine–dopamine releasing agents (NDRAs) like amphetamine and methamphetamine not only induce monoamine release but also
Norepinephrine–dopamine reuptake inhibitor
Norepinephrine–dopamine_reuptake_inhibitor
Chemical compound
selective norepinephrine releasing agent (NRA), or could alternatively be thought of as an imbalanced serotonin–norepinephrine releasing agent (SNRA) or
Phenylpiperazine
Class of compounds
releasing agent (SRA) is a type of drug that induces the release of serotonin into the neuronal synaptic cleft. A selective serotonin releasing agent
Serotonin_releasing_agent
Drug to relieve nasal congestion
regarded as very low. The vast majority of decongestants act via enhancing norepinephrine (noradrenaline) and epinephrine (adrenaline) or adrenergic activity
Decongestant
Psychoactive stimulant and norepinephrine releasing agent
psychostimulant and selective norepinephrine releasing agent (NRA) or norepinephrine-preferring norepinephrine–dopamine releasing agent (NDRA). The EC50Tooltip
Phenylalaninol
Class of drugs
comparatively weak compared to its properties as a serotonin–dopamine–norepinephrine releasing agent. SNDRIs have been studied for a number of indications, but primarily
Serotonin–norepinephrine–dopamine reuptake inhibitor
Serotonin–norepinephrine–dopamine_reuptake_inhibitor
Medications that increase norepinephrine
norepinephrine and epinephrine and therefore can increase adrenergic neurotransmission. A closely related type of drug is a norepinephrine releasing agent
Norepinephrine reuptake inhibitor
Norepinephrine_reuptake_inhibitor
Drug that releases serotonin and dopamine in the brain
100 nM. Monoamine releasing agent Serotonin releasing agent Dopamine releasing agent Serotonin–norepinephrine–dopamine releasing agent Blough BE, Decker
Serotonin–dopamine releasing agent
Serotonin–dopamine_releasing_agent
Emsam) – also a catecholaminergic activity enhancer and weak norepinephrine releasing agent (via metabolites) Discontinued/withdrawn Caroxazone (Surodil
List_of_antidepressants
Topics referred to by the same term
association National Rifle Association, a gun rights advocacy group Norepinephrine releasing agent, a type of drug Nuclear reaction analysis, a nuclear method
NRA
Pharmaceutical compound
(SAR) of phenethylamine and amphetamine MRAs. It acts as a norepinephrine–dopamine releasing agent (NDRA). However, phenylpropylamine is dramatically less
Phenylpropylamine
Class of compounds
neurotransmitters Norepinephrine–dopamine releasing agent (NDRA) (e.g., amphetamine, methamphetamine) Serotonin–norepinephrine releasing agent (SNRA) (e.g.
Monoamine_releasing_agent
Chemical compound
preferential norepinephrine releasing agent, similarly to other related compounds like ephedrine and pseudoephedrine. It acts as a releasing agent of norepinephrine
L-Norpseudoephedrine
Synthetic decongestant
cardiovascular effects than others. Pseudoephedrine acts as a norepinephrine releasing agent, indirectly activating adrenergic receptors. As such, it is
Pseudoephedrine
Behavioral measure in animals
and cocaine-like effects of dopamine releasing agents (DRAs) with varying capacities to release norepinephrine and serotonin in rodents and monkeys have
Locomotor_activity
Protein-coding gene in the species Homo sapiens
these are not suitable for clinical imaging. Norepinephrine Substrate-type norepinephrine releasing agents (e.g., ephedrine, amphetamine) Catecholaminergic
Norepinephrine_transporter
Pharmaceutical compound
monoamine releasing agent and designer drug of the phenylpiperazine family. It acts as a partial serotonin–norepinephrine releasing agent (SNRA), with
2,3-Dimethylphenylpiperazine
Designer stimulant
dopamine and norepinephrine releasing agent (NDRA). The drug has an EC50Tooltip half-maximal effective concentration for dopamine release of 48.7 nM and
2-Fluoromethcathinone
Designer drug
other cathinones, it acts as a monoamine releasing agent, including of serotonin, dopamine, and norepinephrine. However, in contrast to cathinones and
3-Methoxymethcathinone
Chemical compound
Phthalimidopropiophenone Phenylbiguanide Propylhexedrine NRAsTooltip Norepinephrine releasing agents Morpholines: Fenbutrazate Fenmetramide Morazone Morforex Phendimetrazine
1,3-Dimethylbutylamine
Monoaminergic drug
a monoamine releasing agent. As the (–)-enantiomer, it specifically acts as a preferential serotonin and norepinephrine releasing agent (SNRA), with
Α-Methylisotryptamine
Sympathomimetic agent
used as an antihypotensive agent and cough suppressant. It is taken by mouth. Oxilofrine acts as a norepinephrine releasing agent and hence is an indirectly
Oxilofrine
[abuse-deterrent immediate-release] (ADAIR) – norepinephrine–dopamine releasing agent Atomoxetine [oral suspension] – norepinephrine reuptake inhibitor Dextroamphetamine
List of investigational attention deficit hyperactivity disorder drugs
List_of_investigational_attention_deficit_hyperactivity_disorder_drugs
Sympathomimetic agent
Tuaminoheptane has been found to act as a reuptake inhibitor and releasing agent of norepinephrine, which may underlie its decongestant and stimulant effects
Tuaminoheptane
Chemical compound
drug has been shown to act as a norepinephrine–dopamine releasing agent (NDRA) with additional weak serotonin release. Its EC50Tooltip half-maximal effective
3-Chlorophenmetrazine
Chemical compound
similar subjective effects. It acts as a selective serotonin and norepinephrine releasing agent (SNRA). The drug shows greatly reduced serotonergic neurotoxicity
MDAI
Pharmaceutical compound
serotonin–norepinephrine–dopamine releasing agent (SNDRA). The EC50Tooltip half-maximal effective concentration values for induction of monoamine release in
6-MBPB
Decongestant medication
Phenylephrine also has relatively little or no activity as a norepinephrine releasing agent. As such, it has little activity as an indirectly acting sympathomimetic
Phenylephrine
Pharmaceutical compound
pharmacological properties. Like tyramine, hordenine acts as a norepinephrine releasing agent. As of September 2012[update], hordenine is widely sold as an
Hordenine
Chemical compound
a sympathomimetic and ephedrine-like agent. Ephedrine and related agents act as norepinephrine releasing agents and hence as indirectly acting sympathomimetics
Methylephedrine
Withdrawn anti-obesity drug combination
acts as a serotonin releasing agent, phentermine as primarily a norepinephrine releasing agent. Phentermine also induces the release of serotonin and dopamine
Fenfluramine/phentermine
Medication, stimulant and decongestant
breastfeeding is not recommended. Ephedrine works by inducing the release of norepinephrine and hence indirectly activating the α- and β-adrenergic receptors
Ephedrine
Substituted cathinone designer drug
brain) that potently releases and inhibits the reuptake of dopamine and norepinephrine, as well as displaying moderate serotonin releasing activity. 3-Methylmethcathinone
3-Methylmethcathinone
Pharmaceutical drug
for medical use in Italy. Like ephedrine, racephedrine is a releasing agent of norepinephrine and to a much lesser extent of dopamine. Both ephedrine enantiomers
Racephedrine
Catecholamine hormone and neurotransmitter
Norepinephrine (NE), also called noradrenaline (NA) or noradrenalin, is an organic chemical in the catecholamine family that functions in the brain and
Norepinephrine
Pharmaceutical compound
derivative of β-methylphenethylamine. The drug is a partial norepinephrine releasing agent, with an EC50Tooltip half-maximal effective concentration of
Β,N,N-Trimethylphenethylamine
Stimulant and entactogen designer drug
misrepresented tablets and capsules of PMMA. PMMA is a serotonin–norepinephrine releasing agent (SNRA) as well as potent monoamine oxidase inhibitor (MAOI)
Para-Methoxymethamphetamine
Psychoactive drug taken by mouth
serotonin–norepinephrine releasing agent (SNRA) and weak serotonin 5-HT2A receptor agonist. It has substantially less or no significant dopamine-releasing activity
(R)-MDMA
Pharmaceutical compound
serotonin–norepinephrine–dopamine releasing agent (SNDRA). However, ENAP is unusual in being a partial releaser of serotonin and dopamine and a full releaser of
Ethylnaphthylaminopropane
Chemical compound
β-adrenergic receptor partial agonist. It may also act as a norepinephrine releasing agent via its major active metabolite norephedrine. Oxyfedrine is
Oxyfedrine
Antihypotensive medication
metaraminol include reflex bradycardia among others. Metaraminol is a norepinephrine releasing agent and at high doses a α1-adrenergic receptor agonist with some
Metaraminol
Medication used to treat seizures
and status epilepticus. Fenfluramine acts as a serotonin and norepinephrine releasing agent, agonist of the serotonin 5-HT2 receptors, and sigma σ1 receptor
Fenfluramine
Investigational narcolepsy and hypersomnia drugs
antagonists (e.g., caffeine) Norepinephrine releasing agents (NRAs) (e.g., ephedrine, selegiline (via metabolites)) Norepinephrine reuptake inhibitors (NRIs)
List of investigational narcolepsy and hypersomnia drugs
List_of_investigational_narcolepsy_and_hypersomnia_drugs
Pharmaceutical compound
serotonin–norepinephrine–dopamine releasing agent (SNDRA). Its EC50Tooltip half-maximal effective concentration values for induction of monoamine release are
1-Naphthylmethcathinone
Pharmaceutical compound
monoamine releasing agent (MRA) of the amphetamine and benzothiophene families. It acts specifically as a fairly well-balanced serotonin–norepinephrine–dopamine
7-APBT
Chemical compound
333 nM for norepinephrine, dopamine, and serotonin, respectively. Hence, dextroethylamphetamine acts as a norepinephrine–dopamine releasing agent (NDRA) with
Etilamfetamine
Chemical compound
selective norepinephrine releasing agent, but also has affinity for several monoamine receptors. NM-2-AI acts as a highly selective norepinephrine reuptake
NM-2-AI
Medication
into levomethamphetamine and levoamphetamine, which act as norepinephrine releasing agents (NRAs) and may contribute to its therapeutic and adverse effects
Selegiline
MDMA metabolite
(MDA) as a monoamine releasing agent in vitro. Nonetheless, HMA has been found to induce the release of serotonin, norepinephrine, and dopamine with EC50Tooltip
4-Hydroxy-3-methoxyamphetamine
4-Hydroxy-3-methoxyamphetamine
Stimulant drug of the substituted cathinone class
doses. Pentylone acts as a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) and a serotonin releasing agent. Pentylone is banned in Canada, Germany
Pentylone
Pharmacology of the antiparkinsonian and antidepressant selegiline
selective norepinephrine releasing agent and levoamphetamine as an imbalanced and norepinephrine-preferring releasing agent of norepinephrine and dopamine
Pharmacology_of_selegiline
Pharmaceutical compound
similarly to the serotonin–norepinephrine–dopamine releasing agent and entactogen MDMA and the norepinephrine–dopamine releasing agent and stimulant 3-methylamphetamine
PAL-335
Chemical compound
serotonin–norepinephrine–dopamine releasing agent (SNDRA) with EC50Tooltip half-maximal effective concentration values of 117 nM for serotonin release, 325 nM
EDMA
Chemical compound
Morton IK, Hall JM (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 164–.
Corbadrine
Chemical compound
dopamine or its precursors. It is more specifically a norepinephrine–dopamine releasing agent (NDRA) similarly to amphetamine. The metabolites of cathinone
Cathinone
Pharmaceutical compound
releasing agent (MRA) of the benzothiophene family. It acts specifically as a fairly well-balanced serotonin–norepinephrine–dopamine releasing agent (SNDRA)
2-APBT
Central nervous system stimulant prodrug
cause a hypertensive crisis. Norepinephrine reuptake inhibitors (NRIs) like atomoxetine prevent norepinephrine release induced by amphetamines and have
Lisdexamfetamine
Trace amine
phenethylamines as well as the catecholamine neurotransmitters dopamine, norepinephrine, and epinephrine. As an organic compound, phenylethanolamine is a β-hydroxylated
Phenylethanolamine
Chemical compound
The drug acts as a serotonin–norepinephrine releasing agent (SNRA) or as a modestly selective serotonin releasing agent (SSRA), with about 6-fold preference
MEAI
Phenethylamine derivative
concentration of 10,000 nM. Hence, phenacylamine acts as a norepinephrine–dopamine releasing agent (NDRA). Despite its activity in vitro however, phenacylamine
2-Aminoacetophenone
Entactogen drug
interaction data have been reported for BDB. It acts as a serotonin–norepinephrine releasing agent (SNDRA) with only weak effects on dopamine. Animal studies and
1,3-Benzodioxolylbutanamine
Drug that increases wakefulness
releasing agents like amphetamine and methamphetamine Norepinephrine reuptake inhibitors like atomoxetine, reboxetine, and desipramine Norepinephrine
Wakefulness-promoting_agent
Sympathomimetic agent
has been associated with hemorrhagic stroke. PPA acts as a norepinephrine releasing agent, indirectly activating adrenergic receptors. As such, it is
Phenylpropanolamine
CNS stimulant and isomer of amphetamine
as a releasing agent of the monoamine neurotransmitters norepinephrine and dopamine. It is similar to dextroamphetamine in its ability to release norepinephrine
Levoamphetamine
Pharmaceutical compound
specifically as a weak partial serotonin–dopamine releasing agent (SDRA) and serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), with EC50Tooltip
Propylone
Pharmaceutical compound
MDMC). The drug is a very low-potency serotonin–norepinephrine–dopamine releasing agent (SNDRA), with EC50Tooltip half-maximal effective concentration
4-Hydroxy-3-methoxymethcathinone
4-Hydroxy-3-methoxymethcathinone
Pharmaceutical compound
(SDMA; 3T-MDMA). Similarly to MDA, SDA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA) and a non-selective serotonin 5-HT2 receptor agonist
SDA_(drug)
Trace amine
in its action at their common biomolecular targets, is a releasing agent of norepinephrine and dopamine. It is roughly equipotent to amphetamine in this
Phenethylamine
Designer drug combination mimicking MDMA
entactogens acting as serotonin–norepinephrine–dopamine releasing agents (SNDRA) or serotonin–norepinephrine releasing agents (SNRA) 2-Fluoromethamphetamine
Borax_combo
Pharmaceutical compound
are monoamine releasing agents (MRAs) and psychostimulants. 2-Phenylmorpholine itself is a potent norepinephrine–dopamine releasing agent (NDRA) and hence
2-Phenylmorpholine
Pharmaceutical compound
(3Z)-phenylbutenamine (PAL-893). Both of these enantiomers act as norepinephrine–dopamine releasing agents (NDRAs), and to similar comparative extents, albeit with
Phenylbutenamine
Pharmaceutical compound
serotonin–norepinephrine–dopamine releasing agent (SNDRA). Its EC50Tooltip half-maximal effective concentration values for induction of monoamine release are
3,4-Ethylenedioxymethcathinone
3,4-Ethylenedioxymethcathinone
Pharmaceutical compound
releasing agent (MRA) of the arylalkylamine family related to β-phenethylamine and amphetamine. It acts as a norepinephrine–dopamine releasing agent (NDRA)
Phenylbutynamine
Novel chemistry compound
Serdexmethylphenidate Solriamfetol Serotonin–norepinephrine–dopamine reuptake inhibitors (SNDRIs): Mazindol Norepinephrine releasing agents (NRAs): Ephedrine Pseudoephedrine
Alixorexton
Stimulant designer drug of the substituted cathinone class
and Spain. 2-MMC is a serotonin-norepinephrine-dopamine releasing agent, with higher preference for the norepinephrine and dopamine transporters. 2-MMC
2-Methylmethcathinone
Chemical compound
phenylmorpholines with similar structure, it likely acts as a norepinephrine-dopamine releasing agent and may produce effects similar or slightly different to
PDM-35
Pharmaceutical compound
monoamine releasing agent and novel designer drug of the benzofuran family. It acts as a serotonin–norepinephrine–dopamine releasing agent (SNDRA). The
4-APB
Chemical compound
It acts as a serotonin–norepinephrine–dopamine releasing agent (SNDRA), with EC50 values for induction of monoamine release of 175 nM for serotonin,
Ortho-Methylphenylpiperazine
Pharmaceutical compound
serotonin 5-HT2B receptor antagonist. Conversely, its activity as a norepinephrine releasing agent was not reported, and it was inactive at the remaining sites
1Z2MAP1O
Combination of theophylline and ephedrine used to treat asthma
receptor antagonist, and ephedrine, a norepinephrine releasing agent and indirectly acting sympathomimetic agent, which has been used as a bronchodilator
Theophylline/ephedrine
Pharmaceutical compound
therapeutic use. Similarly to MDMA, SDMA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA) and a non-selective serotonin 5-HT2 receptor agonist
SDMA_(drug)
Pharmaceutical compound
Serdexmethylphenidate Solriamfetol Serotonin–norepinephrine–dopamine reuptake inhibitors (SNDRIs): Mazindol Norepinephrine releasing agents (NRAs): Ephedrine Pseudoephedrine
Cleminorexton
treat hypotension, and for other uses Phenylpropanolamine – a norepinephrine releasing agent and indirectly acting sympathomimetic with some peripheral selectivity
Peripherally_selective_drug
Chemical compound
MDMA as a monoamine releasing agent in vitro. Nonetheless, HMMA has been found to induce the release of serotonin, norepinephrine, and dopamine with EC50Tooltip
4-Hydroxy-3-methoxymethamphetamine
4-Hydroxy-3-methoxymethamphetamine
Chemical compound
as a norepinephrine–dopamine releasing agent (NDRA), with EC50Tooltip half-maximal effective concentration values for induction of norepinephrine and dopamine
Phenmetrazine
Chemical class of organic compounds
pseudoephedrine), antidepressants (e.g. bupropion and phenelzine), antiparkinson agents (e.g., selegiline), and vasopressors (e.g., ephedrine), among others. Many
Substituted_phenethylamine
Chemical compound
serotonin–norepinephrine releasing agent (SNRA). Its EC50Tooltip half-maximal effective concentration values for induction of monoamine release are 540 nM
MBDB
Class of compounds in the nervous system
as potent monoamine releasing agents of norepinephrine and dopamine at higher concentrations. The MAE and monoamine releasing agent actions of these compounds
Monoaminergic activity enhancer
Monoaminergic_activity_enhancer
Stimulant drug of the phenethylamine class
serotonin–norepinephrine–dopamine releasing agent (SNDRA), MBDB appears to be a highly selective serotonin–norepinephrine releasing agent (SNRA) and
Phenylisobutylamine
Drug class
Monoamine-depleting agents are a group of drugs which reversibly deplete one or more of the monoamine neurotransmitters – serotonin, dopamine, and norepinephrine. One
Monoamine-depleting_agent
Topics referred to by the same term
transformer Tra gene, a transfer gene Triple releasing agent or serotonin-norepinephrine-dopamine releasing agent Trà Hòa bố để, King of Champa (in what is
TRA
Monoamine releaser and entactogen
as well as 3-indoylmethcathinone, is a serotonin–dopamine releasing agent (SDRA) and putative entactogen of the tryptamine, α-alkyltryptamine
BK-NM-AMT
CNS stimulant and isomer of amphetamine
proteins for the monoamine neurotransmitters (namely the serotonin, norepinephrine and dopamine transporters) either via trace amine-associated receptor
Dextroamphetamine
Investigational pervasive developmental disorder drugs
(ALA-002; 70–80% (R)-MDMA, 20–30% (S)-MDMA) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist
List of investigational autism and pervasive developmental disorder drugs
List_of_investigational_autism_and_pervasive_developmental_disorder_drugs
Chemical compound
Phthalimidopropiophenone Phenylbiguanide Propylhexedrine NRAsTooltip Norepinephrine releasing agents Morpholines: Fenbutrazate Fenmetramide Morazone Morforex Phendimetrazine
Β-Methylphenethylamine
travel, tourism, insurance
NOREPINEPHRINE RELEASING-AGENT
NOREPINEPHRINE RELEASING-AGENT
NOREPINEPHRINE RELEASING-AGENT
NOREPINEPHRINE RELEASING-AGENT
NOREPINEPHRINE RELEASING-AGENT
NOREPINEPHRINE RELEASING-AGENT
NOREPINEPHRINE RELEASING-AGENT
NOREPINEPHRINE RELEASING-AGENT
NOREPINEPHRINE RELEASING-AGENT
travel, tourism, insurance